Inhibition of Proteasomes by Bortezomib Decreases MuRF-1 and MAFbx mRNA Expression in Rat Soleus during Hindlimb Unloading

  • S. P. BelovaEmail author
  • B. S. Shenkman
  • T. L. Nemirovskaya


Skeletal muscle atrophy caused by unloading is accompanied by increased proteolysis and decreased protein synthesis. It is established that in conditions of muscle unloading, concentration of free amino acids is increased. We hypothesized that proteasome inhibition may decrease amino acid accumulation in skeletal muscle and prevent the atrophy. To test this hypothesis, we treated rats with bortezomib (a proteasome inhibitor) during 7-day hindlimb suspension. Content of key signaling proteins of various signaling pathways was measured by Western-blotting; mRNA level of E3 ligases by RT-PCR, rate of protein synthesis by SUnSET technique. Soleus muscle weight and intensity of the protein synthesis in the groups of “hindlimb suspension” (HS) and “HS + bortezomib” (HSB) were equally reduced as compared to control. Levels of MuRF-1 and MAFbx mRNAs, content of MuRF-1 and calpain-1 proteins, and level of the protein ubiquitination were increased only in the HS group and remained unchanged in the HSB group as compared to the control group. We conclude that inhibition of proteasomes during m. soleus unloading prevents increase in activity of some components of catabolic signaling pathways. However, this is not sufficient to reduce rate of the atrophic processes in skeletal muscle.


skeletal muscle atrophy proteasome E3 ubiquitin ligase calpain 



The work was supported by the Russian Foundation for Basic Research (project no. 17-04-01838) and by the Program of Basic Researches SSC RF IMPB RAS (project no. 65.3).


Conflict of interests. The authors declare that they have no conflict of interest.

Statement on the welfare of animals. All procedures were performed in accordance with the European Communities Council Directive (November 24, 1986; 86/609/EEC) and the Declaration on humane treatment of animals. All procedures with the animals were approved by the Biomedicine Ethics Committee of the Institute of Biomedical Problems of the Russian Academy of Sciences/Physiology section of the Russian Bioethics Committee (protocols no. 385, 24.03.2015).


  1. 1.
    Bodine S.C. 2013. Disuse-induced muscle wasting. Int. J. Biochem. Cell Biol. 45, 2200–2208.CrossRefGoogle Scholar
  2. 2.
    Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M, Stitt T.N., Yancopoulos G.D., Glass D.J. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294 (5547), 1704–1708.CrossRefGoogle Scholar
  3. 3.
    Gamrin L, Berg H.E., Essén P., Tesch P.A., Hultman E., Garlick P.J., McNurlan M.A., Wernerman J. 1998. The effect of unloading on protein synthesis in human skeletal muscle. Acta Physiol. Scand. 163 (4), 369–377.CrossRefGoogle Scholar
  4. 4.
    Tawa N.E. Jr., Odessey R., Goldberg A.L. 1997. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 1, 197–203.CrossRefGoogle Scholar
  5. 5.
    Novikov V.E., Ilyin E.A. 1981. Age-related reactions of rat bones to their unloading. Aviat. Space Environ. Med. 52 (9), 551–553.Google Scholar
  6. 6.
    Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. 1999. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59 (11), 2615–2622.Google Scholar
  7. 7.
    van Hees H.W.1., Li Y.P. Ottenheijm C.A., Jin B., Pigmans C.J., Linkels M., Dekhuijzen P.N., Heunks L.M. 2008. Proteasome inhibition improves diaphragm function in congestive heart failure rats. Am. J. Physiol. Lung Cell Mol. Physiol. 294 (6), 1260–1268.CrossRefGoogle Scholar
  8. 8.
    Mlynarczuk-Bialy I., Doeppner T.R., Golab J., Nowis D., Wilczynski G.M., Parobczak K., Wigand M.E., Hajdamowicz M., Biały L.P., Aniolek O., Henklein P., Bähr M., Schmidt B., Kuckelkorn U., Kloetzel P.M. 2014. Biodistribution and efficacy studies of the proteasome inhibitor BSc2118 in a mouse melanoma model. Transl. Oncol. 7 (5), 570–579.CrossRefGoogle Scholar
  9. 9.
    Chen F.T., Yang C.M., Yang C.H. 2013. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina. PLoS One. 8 (5), e64262.CrossRefGoogle Scholar
  10. 10.
    Goodman C.A., Mabrey D.M., Frey J.W., Miu M.H., Schmidt E.K., Pierre P., Hornberger T.A. 2011. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 25 (3), 1028–1039.CrossRefGoogle Scholar
  11. 11.
    Beehler B.C., Sleph P.G., Benmassaoud L., Grover G.J. 2006. Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp. Biol. Med. (Maywood). 231 (3), 335–341CrossRefGoogle Scholar
  12. 12.
    Krawiec B.J., Frost R.A., Vary T.C., Jefferson L.S., Lang C.H. 2005. Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 289 (6), 969–980.CrossRefGoogle Scholar
  13. 13.
    Shenkman B.S., Belova S.P., Lomonosova Y.N., Kostrominova T.Y., Nemirovskaya T.L. 2015. Calpain-dependent regulation of the skeletal muscle atrophy following unloading. Arch. Biochem. Biophys. 584, 36–41.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2019

Authors and Affiliations

  • S. P. Belova
    • 1
    • 2
    Email author
  • B. S. Shenkman
    • 2
  • T. L. Nemirovskaya
    • 1
    • 2
  1. 1.Faculty of Basic Medicine, Moscow Lomonosov State UniversityMoscowRussia
  2. 2.Institute of Biomedical Problems, Russian Academy of SciencesMoscowRussia

Personalised recommendations